Objective:
To evaluate the rationale for using MCO-010 (sonpiretigene isteparvovec) in treating geographic atrophy (GA) following positive results in retinitis pigmentosa (RP) and Stargardt disease.
Approach:
- Presentation Overview: Jordi Monés, MD, PhD, discussed the rationale for evaluating MCO-010 in GA at the American Society of Retina Specialists meeting.
Key Findings:
- MCO-010 has shown positive results in improving visual acuity in RP and Stargardt disease.
- The safety profile of MCO-010 is favorable in both RP and Stargardt patients.
- The new model of GA indicates potential for MCO-010 to improve vision in advanced cases.
Interpretation:
Clinical trials for GA using MCO-010 are anticipated to begin soon, with expectations of improving vision in patients.
Conclusion:
The use of optogenetics with MCO-010 in GA patients is promising based on previous successes in other retinal diseases.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.